Zydus Lifesciences (ZYDUSLIFE) — Financial Results

Zydus Lifesciences reported a 69.9% YoY revenue increase to ₹87.22 crores for the quarter ending March 31, 2025, driven by strong performance in its pharmaceutical segment, though net profit figures were not disclosed in the filing.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ZYDUSLIFE ✨ Ask AI About This

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

💡 Ask AI about this filing

"How does this financial results affect Zydus Lifesciences Limited's outlook?" "What did Zydus Lifesciences Limited announce on 25 March 2025?" "Is this positive or negative for ZYDUSLIFE?"

Ask AI Free →

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

🔥 Also filed on 25 March 2025

RECLTD REC Limited Financial Results SIEMENS Siemens Limited Corporate Action SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results SIEMENS Siemens Limited Corporate Action VBL Varun Beverages Limited Financial Results VBL Varun Beverages Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.